Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCT with Busulfan/Cyclophosphamide/ATG for Immune Deficiencies
NCT00176826Phase 3Terminated
- Sponsor
- Masonic Cancer Center
- Start
- Sep 2000
- Primary completion
- Aug 2012
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of busulfan, cyclophosphamide and antithymocyte globulin rabbit in hemophagocytic lymphohistiocytosis (HLH), X-linked lymphoproliferative disease (XLP), Chediak-Higashi syndrome (CHS) and 7 more, sponsored by Masonic Cancer Center. Primary endpoint: Time to Transplant Engraftment at Day 100. Started Sep 2000; status: terminated.
02
Drugs
busulfancyclophosphamideantithymocyte globulin rabbit
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)X-linked lymphoproliferative disease (XLP)Chediak-Higashi syndrome (CHS)Griscelli syndrome (GS)Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on NCT00176826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00176826.